Background: Malaria remains a major cause of morbidity and mortality in Zambia, affecting all levels of society, with children under the age of five and pregnant women being most at risk of serious illness. The availability of antimalarial medicines is one of the key interventions of malaria management. This study assessed the availability of antimalarial medicines in community pharmacies in Lusaka district, Zambia. Materials and Methods: This was a cross-sectional study that was conducted among 210 community pharmacies from September to November 2022 using a well-structured checklist in selected areas of Lusaka district. The availability was verified by a physical check of the product. The checklist contained the medicines listed both in the guidelines for diagnosis and treatment of malaria in Zambia as well as in the World Health Organization (WHO) malaria treatment guidelines. Results: This study found that all antimalarials listed in the local treatment guidelines for malaria were available in community pharmacies, though with the varying distribution. Of the 210 community pharmacies, 209 (99.5%) had artemether/lumefantrine in stock. The lowest available antimalarial was quinine/clindamycin, which was only available in 3 (1.4%) of the outlets. Conversely, 3 out of 16 (18.8%) antimalarials that were available in community pharmacies were not listed in the local treatment guidelines of malaria in Zambia, despite being listed in the WHO malaria treatment guidelines. This translated into a compliance level of 81.2% based on the local malaria treatment guidelines. Conclusion: This study concluded that antimalarials were available for all categories of malaria management in community pharmacies, though with a varying distribution. The presence of antimalarials not listed in the Zambian treatment guidelines is of public health concern which may have an impact on antimicrobial resistance in the future.
References
[1]
Tizifa, T.A., Kabaghe, A.N., McCann, R.S., et al. (2018) Prevention Efforts for Malaria. Current Tropical Medicine Reports, 5, 41-50.
https://doi.org/10.1007/s40475-018-0133-y
[2]
McDonnell, M.R. (2022) World Malaria Report 2022: What You Need to Know. United to Beat Malaria.
https://beatmalaria.org/blog/world-malaria-report-2022-what-you-need-to-know
[3]
Monroe, A., Williams, N.A., Ogoma, S., et al. (2022) Reflections on the 2021 World Malaria Report and the Future of Malaria Control. Malaria Journal, 21, Article No. 154. https://doi.org/10.1186/s12936-022-04178-7
https://malariajournal.biomedcentral.com/articles/10.1186/s12936-022-04178-7
[4]
World Malaria Report 2021.
https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2021
[5]
World Heal Organ (2017) World Malaria Report 2016—English Summary.
http://apps.who.int/bookorders
[6]
Global Technical Strategy for Malaria 2016-2030 (2021).
https://www.who.int/publications/i/item/9789240031357
Zambia National Malaria Indicator Survey 2021. 1-155.
https://static1.squarespace.com/static/58d002f017bffcf99fe21889/t/632a39376911de08af7c0ece/1663711548328/Zambia+MIS2021_20220719+SIGNED_for+PRINTING.pdf
[9]
ACT Watcgh Group, Tougher, S., Hanson, K. and Goodman, C. (2017) What Happened to Anti-Malarial Markets after the Affordable Medicines Facility-Malaria Pilot? Trends in ACT Availability, Price and Market Share from Five African Countries under Continuation of the Private Sector Co-Payment Mechanism. Malaria Journal, 16, Article No. 173. https://pubmed.ncbi.nlm.nih.gov/28441956
https://doi.org/10.1186/s12936-017-1814-z
[10]
Kaula, H., Buyungo, P. and Opigo, J. (2017) Private Sector Role, Readiness and Performance for Malaria Case Management in Uganda, 2015. Malaria Journal, 16, Article No. 219. https://doi.org/10.1186/s12936-017-1824-x
https://malariajournal.biomedcentral.com/articles/10.1186/s12936-017-1824-x
[11]
Smith, N., Obala, A., Simiyu, C., et al. (2011) Accessibility, Availability and Affordability of Anti-Malarials in a Rural District in Kenya after Implementation of a National Subsidy Scheme. Malaria Journal, 10, Article No. 316.
https://malariajournal.biomedcentral.com/articles/10.1186/1475-2875-10-316
https://doi.org/10.1186/1475-2875-10-316
[12]
Khuluza, F. and Heide, L. (2017) Availability and Affordability of Antimalarial and Antibiotic Medicines in Malawi. PLOS ONE, 12, e0175399.
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0175399
https://doi.org/10.1371/journal.pone.0175399
[13]
Ladner, J., Davis, B., Audureau, E. and Saba, J. (2017) Treatment-Seeking Patterns for Malaria in Pharmacies in Five Sub-Saharan African Countries. Malaria Journal, 16, Article No. 353. https://doi.org/10.1186/s12936-017-1997-3
[14]
World Health Organization (2022) WHO Guidelines for Malaria.
https://www.who.int/publications/i/item/guidelines-for-malaria
[15]
World Health Organization (2021) WHO Guidelines for Malaria.
https://www.who.int/publications/i/item/guidelines-for-malaria
[16]
Ministry of Health Zambia (2017) Guidelines for Diagnosis and Treatment of Malaria in Zambia. 1-59.
https://static1.squarespace.com/static/58d002f017bffcf99fe21889/t/5cb9738a42ffca0001aaedbc/1555657626933/NationalMalariaTreatmentGuidelines2017_Final20170917+%281%29.pdf
[17]
Charan, J. and Biswas, T. (2013) How to Calculate Sample Size for Different Study Designs in Medical Research? Indian Journal of Psychological Medicine, 35, 121-126.
https://pubmed.ncbi.nlm.nih.gov/24049221
https://doi.org/10.4103/0253-7176.116232
[18]
Ministry of Health Zambia (2022) National Malaria Elimination Strategic Plan 2022-2026. 1-61.
https://static1.squarespace.com/static/58d002f017bffcf99fe21889/t/632a4cb0fcd87c13d0165372/1663716530614/ZNMESP+2022+to+2026_SIGNED+120722.pdf
[19]
Kaiser, A.H., Hehman, L., Forsberg, B.C., Simangolwa, W.M. and Sundewall, J. (2019) Availability, Prices and Affordability of Essential Medicines for Treatment of Diabetes and Hypertension in Private Pharmacies in Zambia. PLOS ONE, 14, e0226169. https://doi.org/10.1371/journal.pone.0226169
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0226169
[20]
Kioko, U., Riley, C., Dellicour, S., et al. (2013) A Cross-Sectional Study of the Availability and Price of Anti-Malarial Medicines and Malaria Rapid Diagnostic Tests in Private Sector Retail Drug Outlets in Rural Western Kenya. Malaria Journal, 15, Article No. 359. https://doi.org/10.1186/s12936-016-1404-5
https://malariajournal.biomedcentral.com/articles/10.1186/s12936-016-1404-5
[21]
Ministry of Health (2020) Zambia Standard Treatment Guideline. 1-457.
https://www.moh.gov.zm/?wpfb_dl=32
[22]
News KHP (2021) Launching a Newborn Sickle Cell Screening Programme in Zambia. King’s Health Partners News.
https://www.kingshealthpartners.org/latest/3313-launching-a-newborn-sickle-cell-screening-programme-in-zambia
[23]
Sangho, O., Tounkara, M., Whiting-Collins, L.J., et al. (2021) Determinants of Intermittent Preventive Treatment with Sulfadoxine-Pyrimethamine in Pregnant Women (IPTp-SP) in Mali, a Household Survey. Malaria Journal, 20, Article No. 231. https://doi.org/10.1186/s12936-021-03764-5
https://malariajournal.biomedcentral.com/articles/10.1186/s12936-021-03764-5
[24]
World Health Organization (2013) WHO Policy Brief for the Implementation of Intermittent Preventive Treatment of Malaria in Pregnancy Using Sulfadoxine-Pyrimethamine (IPTp-SP).
https://www.who.int/publications/i/item/WHO-HTM-GMP-2014.4
[25]
Azizi, S.C., Chongwe, G., Chipukuma, H., et al. (2018) Uptake of Intermittent Preventive Treatment for Malaria during Pregnancy with Sulphadoxine-Pyrimethamine (IPTp-SP) among Postpartum Women in Zomba District, Malawi: A Cross-Sectional Study. BMC Pregnancy Childbirth, 18, Article No. 108.
https://bmcpregnancychildbirth.biomedcentral.com/articles/10.1186/s12884-018-1744-y
https://doi.org/10.1186/s12884-018-1744-y
[26]
Dosoo, D.K., Malm, K., Oppong, F.B., et al. (2021) Effectiveness of Intermittent Preventive Treatment in Pregnancy with Sulphadoxine-Pyrimethamine (IPTp-SP) in Ghana. BMJ Global Health, 6, e005877. https://gh.bmj.com/content/6/8/e005877
https://doi.org/10.1136/bmjgh-2021-005877
[27]
Nana, R.R.D., Hawadak, J., Foko, L.P.K., et al. (2022) Intermittent Preventive Treatment with Sulfadoxine Pyrimethamine for Malaria: A Global Overview and Challenges Affecting Optimal Drug Uptake in Pregnant Women. Pathogens and Global Health. https://doi.org/10.1080/20477724.2022.2128563
[28]
Ippolito, M.M., Pringle, J.C., Siame, M., et al. (2020) Therapeutic Efficacy of Artemether-Lumefantrine for Uncomplicated Falciparum Malaria in Northern Zambia. American Journal of Tropical Medicine and Hygiene, 103, 2224-2236.
https://doi.org/10.4269/ajtmh.20-0852
[29]
Nambozi, M., Kabuya, J.B.B., Hachizovu, S., et al. (2017) Artemisinin-Based Combination Therapy in Pregnant Women in Zambia: Efficacy, Safety and Risk of Recurrent Malaria. Malaria Journal, 16, Article No. 199.
https://doi.org/10.1186/s12936-017-1851-7
https://malariajournal.biomedcentral.com/articles/10.1186/s12936-017-1851-7
[30]
Hamainza, B., Masaninga, F., Moonga, H., et al. (2014) Therapeutic Efficacy of Artemether-Lumefantrine on Treatment of Uncomplicated Plasmodium falciparum Mono-Infection in an Area of High Malaria Transmission in Zambia. Malaria Journal, 13, Article No. 430. http://www.malariajournal.com/content/13/1/430
https://doi.org/10.1186/1475-2875-13-430
[31]
Wongsrichanalai, C. and Meshnick, S.R. (2008) Declining Artesunate-Mefloquine Efficacy against Falciparum Malaria on the Cambodia-Thailand Border. Emerging Infectious Diseases, 14, 716-719. https://doi.org/10.3201/eid1405.071601
[32]
Verschuere, J., Decroo, T., Lim, D., et al. (2017) Local Constraints to Access Appropriate Malaria Treatment in the Context of Parasite Resistance in Cambodia: A Qualitative Study. Malaria Journal, 16, Article No. 81.
https://doi.org/10.1186/s12936-017-1732-0
https://malariajournal.biomedcentral.com/articles/10.1186/s12936-017-1732-0
[33]
Noedl, H., Se, Y., Sriwichai, S., et al. (2010) Artemisinin Resistance in Cambodia: A Clinical Trial Designed to Address an Emerging Problem in Southeast Asia. Clinical Infectious Diseases, 51, e82-e89. https://doi.org/10.1086/657120
https://academic.oup.com/cid/article/51/11/e82/376889
[34]
Good Procurement Practices for Artemisinin-Based Antimalarial Medicines. WHO Glob Malar Program. 1-108.
http://apps.who.int/iris/bitstream/handle/10665/44248/9789241598927_eng.pdf;jsessionid=3BE3C9A1D12EB13D461026A398A64C89?sequence=1
[35]
Deepthi, S.P., Anitha, K.B., Rai, M. and Fernandes, A. (2015) Reserve Drug Indent Form and Its Impact on Antimicrobial Consumption and Sensitivity Pattern in the Medical Intensive Care Unit of a Tertiary Care Hospital. Journal of Clinical and Diagnostic Research, 9, 5-9.
[36]
Key Recommendations for Malaria Treatment & Prevention in Nigeria.
https://www.linkedin.com/pulse/key-recommendations-malaria-treatment-prevention-nigeria-chris-c-obi
[37]
Michael, D. and Mkunde, S.P. (2017) The Malaria Testing and Treatment Landscape in Mainland Tanzania, 2016. Malaria Journal, 16, Article No. 202.
https://malariajournal.biomedcentral.com/articles/10.1186/s12936-017-1819-7
https://doi.org/10.1186/s12936-017-1819-7
